

Mitigation and management strategies for ocular event vedotin

Gynecologic Oncology

165, 385-392

DOI: [10.1016/j.ygyno.2022.02.010](https://doi.org/10.1016/j.ygyno.2022.02.010)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer. <i>Annals of Pharmacotherapy</i> , 2023, 57, 585-596.	1.9	6
2	Strategies for Mitigating Antibody-Drug Conjugate Related Adverse Events for Precision Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 496-507.	2.0	1
3	Toxicities From Antibody-Drug Conjugates. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 469-478.	2.0	2
4	A review of the novel tissue factor antibodyâ€“drug conjugate: Tisotumab vedotin. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522211397.	0.9	1
5	The evolving landscape of antibody-drug conjugates in gynecologic cancers. <i>Cancer Treatment Reviews</i> , 2023, 116, 102546.	7.7	13
6	Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine. <i>Gynecologic Oncology Reports</i> , 2023, 47, 101155.	0.6	10
7	Tisotumab vedotin in recurrent or metastatic cervical cancer. <i>Current Problems in Cancer</i> , 2023, 47, 100952.	2.0	9
8	Society of Gynecologic Oncology Journal Club: Controversial conversations in Gynecologic cancer â€“ The ABCs of ADCs (Antibody drug Conjugates). <i>Gynecologic Oncology Reports</i> , 2023, 45, 101141.	0.6	2
9	Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?. <i>Expert Opinion on Investigational Drugs</i> , 2023, 32, 201-211.	4.1	1
10	Integrating antibody drug conjugates in the management of gynecologic cancers. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 420-429.	2.5	8
11	<scp>Exposureâ€“safety</scp> and <scp>exposureâ€“efficacy</scp> analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 0, , .	2.5	1
12	Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey. <i>Cancer Control</i> , 2023, 30, .	1.8	1
13	Antibodyâ€“Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence. <i>Cancers</i> , 2023, 15, 3886.	3.7	19
14	Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 921-928.	2.4	3
15	Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data. <i>Cancer Management and Research</i> , 0, Volume 15, 1063-1072.	1.9	1
16	Ocular surface toxicities associated with modern anticancer therapies. <i>Survey of Ophthalmology</i> , 2023, , .	4.0	1
17	Acute keratoconjunctivitis associated with tisotumab vedotin-tftv for metastatic cervical cancer. <i>American Journal of Ophthalmology Case Reports</i> , 2024, 33, 101979.	0.7	1
18	Antibody-Drug Conjugates in Gynecologic Cancers. <i>Current Treatment Options in Oncology</i> , 2024, 25, 1-19.	3.0	0

#	ARTICLE	IF	CITATIONS
19	Antibody-Drug Conjugates for the Treatment of Gynecologic Cancer. <i>Advances in Oncology</i> , 2024, 4, 73-81.	0.2	0
20	Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody-Drug Conjugates (ADCs). <i>Current Ophthalmology Reports</i> , 2024, 12, 13-22.	1.2	0